Company intelligence / Profile preview

Intensity Therapeutics

Westport, Connecticut, United Statesintensitytherapeutics.com ↗

Ownership: Public · INTS
Development stage: Phase 3

Overview

Clinical results show that INT230‑6 induces rapid tumor necrosis with a favorable safety profile. In a Phase 1/2 study of metastatic sarcomas, median overall survival was reported at over three times that of synthetic controls (21.3 months vs. 6.7 months), with evidence of increased T-cell activation and adaptive immune responses following treatment. Over two hundred patients have been treated across completed trials.

Therapeutic areas: Oncology
Modalities: Small molecules (cytotoxic agents)Intratumoral drug deliveryImmune-based therapies (immune activation)
Industry: Biotech

Drug pipeline

2 assets

INT230-6

1 more asset in the full pipeline.

Request access →

Partnerships

The Swiss Group for Clinical Cancer Research SAKK [for the INVINCIBLE–4 study in TNBC patients].Collaborations with The Ottawa Hospital and Ontario Institute for Cancer Research on clinical trials.

Financials

Market cap: $11.1M
Total revenue: $0
Enterprise value: $1.6M

Beyond the preview

Go deeper on Intensity Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intensity Therapeutics.

Explore the full profile